<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Stopping long‐acting beta2‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids - Ahmad, S - 2015 | Cochrane Library</title> <meta content="Stopping long‐acting beta2‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids - Ahmad, S - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011306.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Stopping long‐acting beta2‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids - Ahmad, S - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011306.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011306.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Stopping long‐acting beta&lt;sub&gt;2&lt;/sub&gt;‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids" name="citation_title"/> <meta content="Shaleen Ahmad" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="kkew@sgul.ac.uk" name="citation_author_email"/> <meta content="Rebecca Normansell" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD011306.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/06/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011306.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011306.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011306.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Withholding Treatment; Administration, Inhalation; Adrenal Cortex Hormones [administration &amp; dosage]; Adrenergic beta‐2 Receptor Agonists [*administration &amp; dosage]; Anti‐Asthmatic Agents [*administration &amp; dosage]; Asthma [*drug therapy]; Randomized Controlled Trials as Topic; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011306.pub2&amp;doi=10.1002/14651858.CD011306.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="Oy81c7tH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011306\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011306\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011306.pub2",title:"Stopping long\\u2010acting beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids",firstPublishedDate:"Jun 19, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011306.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011306.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011306.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011306.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011306.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011306.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011306.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011306.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011306.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011306.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1623 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011306.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/appendices#CD011306-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/table_n/CD011306StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/table_n/CD011306StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Stopping long‐acting beta<sub>2</sub>‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/information#CD011306-cr-0002">Shaleen Ahmad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/information#CD011306-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011306.pub2/information#CD011306-cr-0004">Rebecca Normansell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/information/en#CD011306-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 June 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011306.pub2">https://doi.org/10.1002/14651858.CD011306.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011306-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011306-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011306-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011306-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011306-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011306-abs-0001" lang="en"> <section id="CD011306-sec-0001"> <h3 class="title" id="CD011306-sec-0001">Background</h3> <p>Poorly controlled asthma often leads to preventable exacerbations that require additional medications, as well as unscheduled hospital and clinic visits. </p> <p>Long‐acting beta<sub>2</sub>‐agonists (LABA) are commonly given to adults with asthma whose symptoms are not well controlled by inhaled corticosteroids (ICS). US and UK regulators have issued warnings for LABA in asthma, and now recommend they be used "for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved". </p> </section> <section id="CD011306-sec-0002"> <h3 class="title" id="CD011306-sec-0002">Objectives</h3> <p>To compare cessation of long‐acting beta<sub>2</sub>‐agonists (LABA) versus continued use of LABA/inhaled corticosteroids (LABA/ICS) for adults whose asthma is well controlled, and to determine whether stopping LABA: </p> <p>1. results in loss of asthma control or deterioration in quality of life;<br/> 2. increases the likelihood of asthma attacks or 'exacerbations'; or<br/> 3. increases or decreases the likelihood of serious adverse events of any cause. </p> </section> <section id="CD011306-sec-0003"> <h3 class="title" id="CD011306-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register (CAGR), www.ClinicalTrials.gov, www.who.int/ictrp/en/, reference lists of primary studies and existing reviews and manufacturers' trial registries (GlaxoSmithKline (GSK) and AstraZeneca). We searched all databases from their inception to April 2015, and we imposed no restriction on language of publication. </p> </section> <section id="CD011306-sec-0004"> <h3 class="title" id="CD011306-sec-0004">Selection criteria</h3> <p>We looked for parallel randomised controlled trials (RCTs) of at least eight weeks' duration, in which adults whose asthma was well controlled by any dose of ICS+LABA combination therapy were randomly assigned to (1) step‐down therapy to ICS alone versus (2) continuation of ICS and LABA. </p> </section> <section id="CD011306-sec-0005"> <h3 class="title" id="CD011306-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened all records identified by the search strategy. We used an Excel extraction tool to manage searches, document reasons for inclusion and exclusion and extract descriptive and numerical data from trials meeting inclusion criteria. </p> <p>Prespecified primary outcomes were (1) exacerbations requiring oral steroids, (2) asthma control and (3) all‐cause serious adverse events. </p> </section> <section id="CD011306-sec-0006"> <h3 class="title" id="CD011306-sec-0006">Main results</h3> <p>Six randomised, double‐blind studies between 12 and 24 weeks' long met the inclusion criteria. Five studies contributed data to the meta‐analysis, assigning 2781 people with stable asthma to the comparison of interest. The definition of stable asthma and inclusion criteria varied across studies, and Global Initiative for Asthma (GINA) criteria were not used. Risk of bias across studies was generally low, and most evidence was rated as moderate quality. </p> <p>Stopping LABA might increase the number of people having exacerbations and requiring oral corticosteroids (odds ratio (OR) 1.74, 95% confidence interval (CI) 0.83 to 3.65; participants = 1257; studies = 4), although the confidence intervals did not exclude the possibility that stopping LABA was beneficial; over 17 weeks, 19 people per 1000 who continued their LABA had an exacerbation, compared with 32 per 1000 when LABA were stopped (13 more per 1000, 95% CI 3 fewer to 46 more). </p> <p>People who stopped LABA had worse scores on the Asthma Control Questionnaire (mean difference (MD) 0.24, 95% CI 0.13 to 0.35; participants = 645; studies = 3) and on measures of asthma‐related quality of life (standardised mean difference (SMD) 0.36, 95% CI 0.15 to 0.57; participants = 359; studies = 2) than those who continued LABA, but the effects were not clinically relevant. </p> <p>Too few events occurred for investigators to tell whether stopping LABA has a greater effect on serious adverse events compared with continuing LABA+ICS (OR 0.82, 95% CI 0.28 to 2.42; participants = 1342; studies = 5), and no study reported exacerbations requiring an emergency department visit or hospitalisation as a separate outcome. Stopping LABA may result in fewer adverse events of any kind compared with continuing, although the effect was not statistically significant (OR 0.83, 95% CI 0.66 to 1.05; participants = 1339; studies = 5), and stopping LABA made people more likely to withdraw from participation in research studies (OR 1.95, 95% CI 1.47 to 2.58; participants = 1352; studies = 5). </p> </section> <section id="CD011306-sec-0007"> <h3 class="title" id="CD011306-sec-0007">Authors' conclusions</h3> <p>This review suggests that stopping LABA in adults who have stable asthma while they are taking a combination of LABA and ICS inhalers may increase the likelihood of asthma exacerbations that require treatment with oral corticosteroids, but this is not certain. Stopping LABA may slightly reduce asthma control and quality of life, but evidence was insufficient to show whether this had an effect on important outcomes such as serious adverse events and exacerbations requiring hospital admission, and longer trials are warranted. Trialists should include patient‐important outcomes such as asthma control and quality of life and should use validated measurement tools. Definitions of exacerbations should be provided. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011306-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011306-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011306-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011306-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011306-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011306-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011306-abs-0006">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011306-abs-0004" lang="en"> <h3>What is the evidence for stopping long‐acting beta2‐agonists for adults with stable asthma using combination therapy? </h3> <p>Stopping long‐acting beta<sub>2</sub>‐agonists (LABA) for adults whose asthma is stable with LABA and inhaled corticosteroid (ICS) treatment may increase the number of asthma attacks that require treatment with extra corticosteroids, but this remains uncertain. Stopping LABA may also slightly reduce quality of life and asthma control. We could not tell whether stopping LABA changed serious side effects or the likelihood of having to go to the hospital for an asthma attack. </p> <p><b>Why is the question important?</b> </p> <p>Poorly controlled asthma often leads to attacks that require additional medications, hospital stays or treatment in the emergency department. Long‐acting beta<sub>2</sub>‐agonists (LABA) are inhaled drugs that can be added to inhaled corticosteroids (ICS) to improve symptoms and reduce asthma attacks for adults whose asthma is not well controlled by ICS alone. However, some drug authorities have issued warnings for LABA in asthma because of safety concerns and now recommend that they be used for the shortest duration possible, then stopped once control of asthma symptoms is achieved. We believed it was important to assess evidence provided by high‐quality studies. </p> <p><b>How did we answer the question?</b> </p> <p>We looked for studies at least 8 weeks' long that compared a group of people with stable asthma who stopped taking LABA versus a group who continued taking ICS+LABA together. We were mainly interested in determining whether stopping LABA had an effect on asthma attacks, asthma control or side effects. </p> <p><b>What did we find out?</b> </p> <p>We included in the data analyses five studies of people with stable asthma. We rated the overall quality of evidence as moderate for most outcomes, meaning that additional studies are likely to change our confidence in what we found. It looked as though people who stopped LABA might be more likely to have asthma attacks needing treatment with oral steroids, but this is uncertain. Over 17 weeks, 19 of 1000 people continuing their LABA had an attack, compared with 32 of 1000 who stopped taking LABA. This means that 13 more people in 1000 would have an attack if they stopped their LABA, but the uncertainty meant that between 3 fewer and 46 more could be affected. </p> <p>Asthma control and asthma‐related quality of life were a bit worse among people who stopped taking LABA, and we could not tell whether stopping LABA increased serious side effects or admission to the hospital. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011306-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011306-sec-0088"></div> <h3 class="title" id="CD011306-sec-0089">Implications for practice</h3> <section id="CD011306-sec-0089"> <p>This review suggests that stopping LABA in adults who have stable asthma while taking a combination of LABA and ICS inhalers may increase the likelihood of asthma exacerbations requiring treatment with systemic corticosteroids, but this was not certain. Stopping LABA may slightly reduce asthma control and quality of life, but evidence was insufficient to permit judgement on the possibility of an effect on other important outcomes such as serious adverse events and exacerbations requiring hospital admission. </p> </section> <h3 class="title" id="CD011306-sec-0090">Implications for research</h3> <section id="CD011306-sec-0090"> <p>Given the clinical importance of this question and its relevance to international guidelines, it is perhaps surprising that only six studies met our inclusion criteria, leading to limited conclusions. Given the relative infrequency of exacerbations, especially severe exacerbations, longer trials are warranted. Trialists should include patient‐important outcomes such as asthma control and quality of life and should use validated measurement tools. Definitions of exacerbations should be provided, Our inability to perform subgroup analysis according to baseline ICS dose suggests that further trials examining the effects of stepping down for those requiring higher doses of ICS are warranted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011306-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011306-sec-0022"></div> <div class="table" id="CD011306-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Stopping LABA compared with continuing use of LABA+ICS for adults with well‐controlled asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Stopp ing LABA compared with continuing use of LABA+ICS for adults with well‐controlled asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with asthma well controlled on LABA and ICS<br/> <b>Settings</b> : outpatient<br/> <b>Intervention</b> : LABA stopped<br/> <b>Comparison</b>: LABA continued </p> <p>Both groups were taking the same dose of ICS</p> <p><b>Time point</b>: calculated as the weighted mean duration of studies contributing to each analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>LABA continued</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> LABA stopped</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation: systemic corticosteroids</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (16 to 65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.74</b> <br/> (0.83 to 3.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1257<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma control: ACQ</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ACQ score in the control group was 0.68<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean score of people who stopped LABA was <b>0.24 points worse</b> (0.13 higher to 0.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>645<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID = 0.5, so difference is not clinically significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (4 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.82</b> <br/> (0.28 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1342<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma‐related quality of life</b> </p> <p>12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean asthma‐related quality of life in the control group was 1.18</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean score of people who stopped LABA was <b>0.36 standard deviations worse</b> (0.15 worse to 0.57 worse) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c,</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation: hospital</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1342<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No one in either group was hospitalised for an asthma exacerbation</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (all)</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>521 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000<br/> (417 to 533) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b> <br/> (0.66 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1339<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal (all)</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>269 per 1000<br/> (217 to 327) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.95</b> <br/> (1.47 to 2.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1352<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g.median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : Confidence interval; <b>OR</b> : Odds ratio; <b>LABA</b>: Long‐acting beta<sub>2</sub>‐agonists; <b>ICS</b> : Inhaled corticosteroids; <b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b>: Asthma Quality of Life Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality</b> : Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Confidence intervals include both significant harm and possible benefit of stopping LABA. </p> <p><sup>b</sup>Confidence intervals include significant benefit and harm of either treatment strategy, and 16 events were reported across all studies. </p> <p><sup>c</sup>Quality of life and asthma control are important patient‐centred outcomes and were not reported by at least 3 studies (‐1 publication bias). </p> <p><sup>d</sup>Difficult to judge imprecision because the data were analysed with SMD (Reddel used the Marks AQLQ, and Berger used the Juniper, which are coded in opposite directions on different scales). The Juniper has an MCID of 0.5, and the MD between groups in this study was 0.37 (no downgrade). </p> <p><sup>e</sup>No events were observed, so it was impossible to discern a difference between groups. This may be due to the length of the trials and the severity of illness of the population (‐2 imprecision). </p> <p><sup>f</sup>Confidence intervals include significant benefit of stopping LABA and do not exclude benefit of continuing LABA. </p> <p><sup>g</sup>We planned to look at total withdrawal as it is not affected by the possible bias of assigning reasons for dropouts, but for this reason we were unable to make assumptions about why participants were more likely to withdraw from the trial if they stopped their LABA. </p> <p><sup>h</sup>Weighted mean of control group scores in <a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a> and <a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a> (<a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a> not included in calculation, as researchers reported data as change from baseline). </p> <p><sup>i</sup>Control group endpoint score on the Marks AQLQ in <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>. <a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a>, the only other study in the analysis, reported change from baseline on the Juniper scale. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011306-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011306-sec-0023"></div> <section id="CD011306-sec-0024"> <h3 class="title" id="CD011306-sec-0024">Description of the condition</h3> <p>Asthma is a long‐term condition that affects the airways and is associated with varying degrees of cough, wheeze, shortness of breath and chest tightness. Despite advances in management, asthma continues to pose a significant economic burden, costing the National Health Service a billion pounds each year and causing more than a million lost working days (<a href="./references#CD011306-bbs2-0036" title="British Thoracic Society. Adult asthma audit report 2011. https://www.brit‐thoracic.org.uk/audit‐and‐quality‐improvement/ (accessed 9 June 2014). ">BTS 2011</a>). Costs to the health service include direct drug and treatment costs, but a significant burden comes from poorly controlled asthma leading to preventable exacerbations that require hospital stay or treatment in the emergency department (<a href="./references#CD011306-bbs2-0036" title="British Thoracic Society. Adult asthma audit report 2011. https://www.brit‐thoracic.org.uk/audit‐and‐quality‐improvement/ (accessed 9 June 2014). ">BTS 2011</a>). </p> <p>Asthma prevalence is thought to have stabilised after increases between 1960 and 2000. Changes varied geographically and have been linked to various factors, including air pollution, tobacco legislation, diet and prevalence of other atopic diseases (<a href="./references#CD011306-bbs2-0030" title="AndersonHR . Prevalence of asthma. BMJ2005;330:1037. ">Anderson 2005</a>). Current estimates of UK asthma prevalence are around 8% for adults and 9% for children, translating to 5.4 million people currently receiving treatment (<a href="./references#CD011306-bbs2-0031" title="AsthmaUK . Asthma facts and FAQs. http://www.asthma.org.uk/asthma‐facts‐and‐statistics (accessed 9 June 2014). ">Asthma UK</a>). It is estimated that the worldwide prevalence of asthma is 250 million, with most of the burden of disease reported in low‐ and middle‐income countries (<a href="./references#CD011306-bbs2-0046" title="Global Asthma Network. Global Asthma Report 2014. http://www.globalasthmareport.org/ (accessed 22 August 2014). ">Global Asthma Report 2014</a>). </p> <p>The approach to asthma management is stepwise, to gain symptom control and reduce future risks of exacerbation with minimum effective doses of medication. Therapy at step 1 consists of an as‐required short‐acting beta<sub>2</sub>‐agonist (SABA) for symptom control (<a href="./references#CD011306-bbs2-0045" title="Global Initiative for Asthma(GINA) . Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014). ">GINA 2014</a>). Although some people with asthma can manage their symptoms with as‐required medications (e.g. salbutamol), around two‐thirds require regular treatment with inhaled corticosteroids alone or in combination with other longer‐acting bronchodilator medications (<a href="./references#CD011306-bbs2-0049" title="HoareJ , BruceM , MajeedFA . Prevalence of treated asthma and its management in general practice in England and Wales. Health Statistics Quarterly2003;17:15‐22. ">Hoare 2003</a>). Several national guidelines are available for the treatment of patients with asthma in community and emergency settings, and these recommend broadly similar treatment steps aimed at achieving and maintaining daily symptom control while preventing exacerbations (<a href="./references#CD011306-bbs2-0037" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 6 June 2014). ">BTS/SIGN 2012</a>; <a href="./references#CD011306-bbs2-0045" title="Global Initiative for Asthma(GINA) . Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014). ">GINA 2014</a>; <a href="./references#CD011306-bbs2-0053" title="National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (accessed 6 June 2014). ">NAEPP 2007</a>). </p> </section> <section id="CD011306-sec-0025"> <h3 class="title" id="CD011306-sec-0025">Description of the intervention</h3> <p>Inhaled corticosteroids (ICS) are the primary recommended prevention therapy for people with persistent asthma who do not gain sufficient control by using as‐needed reliever medications (step 2) (<a href="./references#CD011306-bbs2-0037" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 6 June 2014). ">BTS/SIGN 2012</a>; <a href="./references#CD011306-bbs2-0045" title="Global Initiative for Asthma(GINA) . Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014). ">GINA 2014</a>). Regular use of ICS has been shown to improve lung function while reducing the need for reliever medications (<a href="./references#CD011306-bbs2-0028" title="AdamsNP , BestallJB , MaloufR , LassersonTJ , JonesPW . Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD002738.pub2] ">Adams 2008</a>; <a href="./references#CD011306-bbs2-0029" title="AdamsNP , BestallJC , LassersonTJ , JonesP , CatesCJ . Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003135.pub4] ">Adams 2009</a>). </p> <p>National treatment guidelines recommend long‐acting beta<sub>2</sub>‐agonists (LABA) as the preferred add‐on therapy to ICS when a person does not achieve asthma control with ICS and short‐acting reliever medication (<a href="./references#CD011306-bbs2-0037" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 6 June 2014). ">BTS/SIGN 2012</a>; <a href="./references#CD011306-bbs2-0045" title="Global Initiative for Asthma(GINA) . Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014). ">GINA 2014</a>). Combination therapy with LABA+ICS can be given at low dose at step 3, and at medium or high dose at step 4. Evidence from randomised trials has shown that adding LABA to ICS improves lung function and symptoms, and reduces the frequency of exacerbations, in adults whose asthma is not well controlled by ICS alone (<a href="./references#CD011306-bbs2-0041" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2] ">Ducharme 2008</a>), and that this approach is preferable to increasing ICS dose (<a href="./references#CD011306-bbs2-0042" title="DucharmeFM , Ni ChoininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2] ">Ducharme 2010</a>). </p> <p>However, despite demonstrated benefits of LABA add‐on therapy in adults, large studies and meta‐analyses have shown a link between beta<sub>2</sub>‐agonist use and increased asthma morbidity and mortality (<a href="./references#CD011306-bbs2-0039" title="CatesCJ , WielandLS , OleszczukM , KewKM . Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD010314.pub2] ">Cates 2014</a>; <a href="./references#CD011306-bbs2-0056" title="NelsonHS , WeissST , BleeckerER , YanceySW , DorinskyPM , SMART Study Group. The salmeterol multicenter asthma research trial. Chest2006;129:15‐26. ">Nelson 2006</a>; <a href="./references#CD011306-bbs2-0059" title="SalpeterSR , BuckleyNS , OrmistonTM , SalpeterEE . Meta‐analysis: effect of long‐acting beta‐agonists on severe asthma exacerbations and asthma related deaths. Annals of Internal Medicine2006;144:904‐12. ">Salpeter 2006</a>), leading in 2005 to a US Food and Drug Administration (FDA) black box warning — the most severe warning applied to prescription medication to highlight increased risk of serious adverse events (<a href="./references#CD011306-bbs2-0027" title='AaronsonDW . The "black box" warning and allergy drugs. Journal of Allergy and Clinical Immunology2006 Jan;117(1):40‐4. [PUBMED: 16387582] '>Aaronson 2006</a>). FDA analyses of clinical trials showed "increased risk of severe worsening of asthma symptoms, leading to hospitalisation in both children and adults and death in some patients with asthma" (<a href="./references#CD011306-bbs2-0044" title="United StatesFood , DrugAdministration . FDA Drug Safety Communication. New safety requirements for long‐acting inhaled asthma medications called long‐acting beta‐agonists (LABAs). http://www.fda.gov/Drugs/DrugSafety/ (accessed 29 May 2014). ">FDA 2010</a>). As a result, the FDA has mandated that drug companies must conduct clinical trials to assess the safety of LABA used in asthma, with trials expected to yield results by 2017. It has not been established whether either of the two most widely used LABA — salmeterol or formoterol — is safer than the other in adult asthma (<a href="./references#CD011306-bbs2-0039" title="CatesCJ , WielandLS , OleszczukM , KewKM . Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD010314.pub2] ">Cates 2014</a>). </p> <p>Although investigators have shown that the detrimental effects of regular LABA are reduced when used in combination with ICS (<a href="./references#CD011306-bbs2-0039" title="CatesCJ , WielandLS , OleszczukM , KewKM . Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD010314.pub2] ">Cates 2014</a>; <a href="./references#CD011306-bbs2-0043" title="ErnstP , McIvorA , DucharmeFM , BouletLP , FitzgeraldM , ChapmanKR , et al. Safety and effectiveness of long‐acting inhaled beta‐agonist bronchodilators when taken with inhaled corticosteroids. Annals of Internal Medicine2006;146(9):692‐4. ">Ernst 2006</a>), particularly when the two drugs are delivered in a combination inhaler (<a href="./references#CD011306-bbs2-0044" title="United StatesFood , DrugAdministration . FDA Drug Safety Communication. New safety requirements for long‐acting inhaled asthma medications called long‐acting beta‐agonists (LABAs). http://www.fda.gov/Drugs/DrugSafety/ (accessed 29 May 2014). ">FDA 2010</a>), a Cochrane review was not able to conclude whether risk of adverse events remains higher with the combination than with ICS alone (<a href="./references#CD011306-bbs2-0041" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2008, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2] ">Ducharme 2008</a>). In line with the stepwise approach to asthma treatment (<a href="./references#CD011306-bbs2-0037" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. http://www.brit‐thoracic.org.uk/guidelines/asthma‐guidelines.aspx (accessed 6 June 2014). ">BTS/SIGN 2012</a>; <a href="./references#CD011306-bbs2-0045" title="Global Initiative for Asthma(GINA) . Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014). ">GINA 2014</a>), manufacturers' labels are required to state that LABA should be used only "for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved". </p> </section> <section id="CD011306-sec-0026"> <h3 class="title" id="CD011306-sec-0026">How the intervention might work</h3> <p>Inhaled corticosteroids reduce mucus buildup and exacerbations by reducing inflammation in the airways (<a href="./references#CD011306-bbs2-0032" title="BarnesPJ , AdcockI . Anti‐inflammatory actions of steroids: molecular mechanisms. Trends in Pharmacological Sciences1993;14:436‐41. ">Barnes 1993</a>), and can be taken once (fluticasone furoate) or twice daily (e.g. beclomethasone, budesonide, fluticasone propionate). LABA can also be taken once (vilanterol) or twice daily (formoterol, salmeterol), and act as a bronchodilator by relaxing bronchial wall smooth muscle (<a href="./references#CD011306-bbs2-0055" title="NelsonHS . Beta‐adrenergic bronchodilators. New England Journal of Medicine1995;333(8):449‐506. ">Nelson 1995</a>). </p> <p>Much debate has surrounded possible causal links between LABA and increased mortality and morbidity (<a href="./references#CD011306-bbs2-0038" title="CatesCJ , CatesMJ . Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3] ">Cates 2012</a>; <a href="./references#CD011306-bbs2-0060" title="TattersfieldAE . Current issues with beta2‐adrenoceptor agonists: historical background. Clinical Reviews in Allergy and Immunology2006;31(2‐3):107‐18. ">Tattersfield 2006</a>). Theories of LABA‐related death and adverse events include direct toxicity of the drugs themselves (in particular, their cardiac effects (e.g. <a href="./references#CD011306-bbs2-0034" title="BrownMJ , BrownDC , MurphyMB . Hypokalemia from beta2‐receptor stimulation by circulating epinephrine. New England Journal of Medicine1983;309(23):1414‐9. ">Brown 1983</a>)), reduced response over time causing gradual worsening of disease (<a href="./references#CD011306-bbs2-0052" title="LipworthBJ . Airway subsensitivity with long‐acting beta2‐agonists: is there a cause for concern?. Drug Safety1997;16(5):295‐30. ">Lipworth 1997</a>) and delay in receiving medical help caused by masking of underlying inflammation (the delay hypothesis (e.g. <a href="./references#CD011306-bbs2-0033" title="Bijl‐HoflandID , CloostermanSG , FolgeringHT , van denElshoutFJ , vanWeelC , vanSchayckCP . Inhaled corticosteroids, combined with long‐acting beta2‐agonists, improve the perception of bronchoconstriction in asthma. American Journal of Respiratory and Critical Care Medicine2001;164(5):764‐9. ">Bijl‐Hofland 2001</a>)). It has been suggested that the delay hypothesis is linked to a reduction in compliance with appropriate ICS treatment (<a href="./references#CD011306-bbs2-0050" title="JohnstonSL , EdwardsMR . Mechanisms of adverse effects of {beta}‐agonists in asthma. Thorax2009;64(9):739‐41. [PUBMED: 19717707 ] ">Johnston 2009</a>), although this is largely a historical issue that has arisen since the introduction of combination inhalers. Confounding by severity, in the sense that people with more severe disease are likely to be taking LABA, has now been dismissed, as it cannot explain the overall increase in mortality reported in the 1960s and 1970s, and in the light of evidence from large case‐control studies (e.g. <a href="./references#CD011306-bbs2-0040" title="CraneJ , PearceN , FlattA , BurgessC , JacksonR , KwongT , et al. Prescribed fenoterol and death from asthma in New Zealand. Lancet1989;1(8644):917‐22. ">Crane 1989</a>). </p> <p>A UK confidential inquiry into asthma mortality in 2012‐2013 identified 195 deaths attributable to asthma (<a href="./references#CD011306-bbs2-0054" title="Royal College of Physicians. Why asthma still kills: the National Reviewof Asthma Deaths (NRAD). https://www.rcplondon.ac.uk/sites/default/files/why‐asthma‐still‐kills‐full‐report.pdf (accessed 22 August 2014). ">National Review of Asthma Deaths (NRAD) 2014</a>). Of these, a significant proportion of patients showed poor compliance with medication regimens (48%) or were overusing short‐acting beta<sub>2</sub>‐agonists (39%) — potential confounding factors that could influence outcomes in this review. </p> </section> <section id="CD011306-sec-0027"> <h3 class="title" id="CD011306-sec-0027">Why it is important to do this review</h3> <p>Despite established evidence of safety issues associated with use of LABA in uncontrolled asthma, only limited data are available to support or guide discontinuation once asthma control is achieved. It is unclear whether potential risks of stopping LABA for patients who have achieved asthma control (i.e. increased likelihood of exacerbations and reduced quality of life) outweigh potential risks of continuing LABA therapy. </p> <p>The risk‐benefit ratio may be different in children and adolescents, as "the risks of hospitalisation and poor outcomes are of particular concern for children" (<a href="./references#CD011306-bbs2-0044" title="United StatesFood , DrugAdministration . FDA Drug Safety Communication. New safety requirements for long‐acting inhaled asthma medications called long‐acting beta‐agonists (LABAs). http://www.fda.gov/Drugs/DrugSafety/ (accessed 29 May 2014). ">FDA 2010</a>), and particular issues with compliance may be seen among the younger population. For this reason, all child and adolescent studies will be synthesised in a separate review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011306-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011306-sec-0028"></div> <p>To compare cessation of long‐acting beta<sub>2</sub>‐agonists (LABA) versus continued use of LABA/inhaled corticosteroids (LABA/ICS) for adults whose asthma is well controlled, and to determine whether stopping LABA: </p> <p>1. results in loss of asthma control or deterioration in quality of life;<br/> 2. increases the likelihood of asthma attacks or 'exacerbations'; or<br/> 3. increases or decreases the likelihood of serious adverse events of any cause. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011306-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011306-sec-0029"></div> <section id="CD011306-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011306-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included parallel randomised controlled trials (RCTs) of at least 8 weeks' duration. We included studies reported as full‐text articles, those published as abstracts only and unpublished data. We did not include cross‐over trials, as they are not suitable for assessing long‐term outcomes. </p> </section> <section id="CD011306-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies of adults age 18 or older whose asthma is currently well controlled with any dose of maintenance long‐acting beta<sub>2</sub>‐agonists (LABA) and inhaled corticosteroids (ICS). Participants' asthma control was classified according to prespecified criteria (e.g. a score lower than 1.5 on the Asthma Control Questionnaire (ACQ)), or the criteria for control described in <a href="./references#CD011306-bbs2-0045" title="Global Initiative for Asthma(GINA) . Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014). ">GINA 2014</a> guidelines (i.e. daytime symptoms and need for rescue inhaler twice or less often per week, with no nocturnal symptoms or limitations in daily activities). </p> <p>If researchers included both adults and children and did not provide data for adults alone, we included studies if mean age was over 18 in both groups of participants. When studies were found that included only a subset of relevant participants, we included them only if study authors were able to provide disaggregated data for participants who fit the inclusion criteria. We excluded studies that included participants with other chronic respiratory co‐morbidities (e.g. chronic obstructive pulmonary disease). </p> </section> <section id="CD011306-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included studies in which adults whose asthma was well controlled by any dose of ICS+LABA combination therapy were randomly assigned to: </p> <p> <ol id="CD011306-list-0001"> <li> <p>step‐down therapy to ICS alone (continued at the same dose received before randomisation); or </p> </li> <li> <p>continued use of ICS and LABA (any preparation at the same dose received before randomisation).</p> </li> </ol> </p> <p>We included any LABA (formoterol, salmeterol, vilanterol) and any dose of ICS (budesonide, mometasone, fluticasone propionate, fluticasone furoate) used to treat asthma delivered in a combination inhaler or in separate inhalers. We allowed studies in which researchers gave a different ICS to participants in the intervention group, provided it was given at the same beclomethasone dipropionate (BDP) equivalent dose as the ICS received before LABA was stopped, as this may reflect what happens in practice (e.g. replacing salmeterol/fluticasone with beclomethasone). </p> <p>One possible treatment strategy for asthma at step 4 is to reduce the dose of LABA and ICS concurrently, once asthma control has been achieved (rather than stopping LABA); however, we did not include in the review studies addressing the effects of this intervention, as this is a separate clinical question. </p> <p>We included trials that allowed short‐acting reliever medications, provided they were not given as part of the randomly assigned treatment. </p> </section> <section id="CD011306-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD011306-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011306-list-0002"> <li> <p>Exacerbation requiring systemic corticosteroids.</p> </li> <li> <p>Asthma control* (measured on a validated scale, e.g. Asthma Control Questionnaire (ACQ)). </p> </li> <li> <p>Serious adverse events (all cause).</p> </li> </ol> </p> <p>Primary outcomes were chosen to represent an important measure of resource use, a patient‐important outcome and safety. </p> </section> <section id="CD011306-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011306-list-0003"> <li> <p>Quality of life* (measured on a validated scale, e.g. Asthma Quality of Life Questionnaire).</p> </li> <li> <p>Exacerbations requiring hospitalisation or emergency department visit (participants with at least one). </p> </li> <li> <p>Adverse events (all cause).</p> </li> <li> <p>Withdrawals.</p> </li> </ol> </p> <p>Reporting in the trial one or more of the outcomes listed here was not an inclusion criterion for the review. </p> <p>*If more than one scale measuring the same construct is reported within a study, or if different scales are used across studies, we will analyse results using standardised mean differences. </p> </section> </section> </section> <section id="CD011306-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011306-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Trials Search Co‐ordinator for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED) and PsycINFO, and by handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD011306-sec-0094">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy presented in <a href="./appendices#CD011306-sec-0100">Appendix 2</a>. </p> <p>We also conducted a search of ClinicalTrials.gov (www.ClinicalTrials.gov) and the World Health Organization (WHO) trials portal (www.who.int/ictrp/en/). We searched all databases from their inception up to April 2015, and we imposed no restriction on language of publication. </p> </section> <section id="CD011306-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles to look for additional references. We searched relevant manufacturers' websites (GlaxoSmithKline (GSK) and AstraZeneca) for trial information, and we contacted field experts to request information about unpublished or ongoing studies. </p> <p>On 3 March 2015, we searched for errata or retractions from included studies published in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed). </p> </section> </section> <section id="CD011306-sec-0040"> <h3 class="title" id="CD011306-sec-0040">Data collection and analysis</h3> <section id="CD011306-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KK and SA) independently screened titles and abstracts for inclusion of all potential studies identified as a result of the search, and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved the full‐text study reports or publications, and two review authors (KK and SA) independently screened the full‐text articles to identify studies for inclusion. We identified and recorded reasons for exclusion of ineligible studies, resolving disagreements through discussion or, if required, by consultation with a third person. We identified and excluded duplicates and collated multiple reports of the same study, so that each study, rather than each report, is the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) flow diagram and a <a href="./references#CD011306-sec-0109" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD011306-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We used a Microsoft Excel data collection form, which has been piloted on at least one study in the review, to document study characteristics and outcome data. Both review authors (KK and SA) extracted the following study characteristics from included studies. </p> <p> <ol id="CD011306-list-0004"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study setting, withdrawals, date of study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, time points reported.</p> </li> <li> <p>Notes: funding for trial, notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>One review author (KK) independently extracted outcome data from included studies. We noted in the <a href="./references#CD011306-sec-0108" title="">Characteristics of included studies</a> table if outcome data were not reported in a useable way. We resolved disagreements by reaching consensus or by involving a third person. One review author (KK) transferred data into the Review Manager (<a href="./references#CD011306-bbs2-0058" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager (RevMan)</a>) file. We double‐checked that data were entered correctly by comparing data presented in the systematic review versus those provided in the study reports. A second review author (SA) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD011306-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KK and SA) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011306-bbs2-0048" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved disagreements by discussion or through involvement of a third person. We assessed risk of bias according to the following domains. </p> <p> <ol id="CD011306-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear, and provided a quote from the study report, together with a justification for our judgement, in the 'Risk of bias' table. We summarised 'Risk of bias' judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes when necessary (e.g. for unblinded outcome assessment, risk of bias will be greater for quality of life ratings than for number of exacerbations). When information on risk of bias was related to unpublished data or correspondence with a study author, we noted this in the 'Risk of bias' table. </p> <p>When uncertainties were due to insufficient reporting, we contacted the study author or the sponsor for additional information. </p> <p>When considering treatment effects, we took into account risk of bias for studies that contributed to this outcome. </p> <section id="CD011306-sec-0044"> <h5 class="title">Assesment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol and reported deviations from it in the <a href="#CD011306-sec-0106">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD011306-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios, and continuous data as mean differences or standardised mean differences. We entered data presented as a scale with a consistent direction of effect. We narratively described skewed data reported as medians and interquartile ranges. </p> <p>We undertook meta‐analyses only when this was meaningful (i.e. when treatments, participants and the underlying clinical question were similar enough for pooling to make sense). </p> <p>When multiple trial arms were reported in a single trial, we included only the relevant arms. When two comparisons (e.g. drug A vs placebo and drug B vs placebo) were combined in the same meta‐analysis, we halved the control group to avoid double‐counting. </p> <p>When changes from baseline and endpoint scores were available for continuous data, we used changes from baseline unless most studies reported endpoint scores. When a study reported outcomes at multiple time points, we used the end‐of‐study measurement. </p> <p>When both an analysis using only participants who completed the trial and an analysis imputing data for participants who were randomly assigned but did not provide endpoint data (e.g. last observation carried forward) were available, we used the latter. </p> </section> <section id="CD011306-sec-0046"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, we used participants rather than events as the unit of analysis (i.e. number of adults admitted to the hospital rather than number of admissions per adult). However, if exacerbations were reported as rate ratios, we analysed them on this basis. </p> </section> <section id="CD011306-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study was identified as an abstract only). When this was not possible, and missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by performing a sensitivity analysis<b>. </b> </p> </section> <section id="CD011306-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity, we reported this and explored possible causes by performing prespecified subgroup analyses.  </p> </section> <section id="CD011306-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>As we did not have more than 10 trials for pooling, we did not create and examine a funnel plot to explore possible small study and publication biases. We considered the impact of unpublished trials in the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) ratings for each outcome (<a href="./references#CD011306-bbs2-0047" title="BrozekJ , OxmanA , SchünemannH . GRADEpro, Version 3.2 for Windows. Ontario, Canada: McMasters, 2008. ">GRADEpro</a>; <a href="./references#CD011306-bbs2-0048" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011306-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model for all analyses, as we expected variation in effects due to differences in study populations and methods. We performed sensitivity analyses using a fixed‐effect model. </p> <section id="CD011306-sec-0051"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table to present data for the seven prespecified outcomes<i>.</i> We presented the pooled analysis in each case, and noted in the comments column significant differences between subgroups. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it related to studies that contributed data to the meta‐analyses for prespecified outcomes. We used methods and recommendations as described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011306-bbs2-0048" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) by using GRADEpro software. We justified all decisions to downgrade or upgrade the quality of studies by using footnotes, and we made comments when necessary to aid the reader's understanding of the review. </p> </section> </section> <section id="CD011306-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses for primary outcomes, using the formal test for subgroup differences provided in Review Manager (version 5.3) (<a href="./references#CD011306-bbs2-0058" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager (RevMan)</a>). </p> <p> <ol id="CD011306-list-0006"> <li> <p>Mean steroid dose (according to <a href="http://archie.cochrane.org/sections/documents/view?document=z1405201158356969485713945219635%26format=REVMAN#REF-GINA-2014" target="_blank">GINA 2014</a>, defined as low, medium and high cutoffs). </p> </li> <li> <p>Type of inhaler used in the comparison group (LABA/ICS combination inhaler vs separate inhalers). </p> </li> <li> <p>Type of LABA being stopped (formoterol, salmeterol).</p> </li> </ol> </p> <p>Mean steroid dose of the population in each study may reflect differences in disease severity and may have effects on outcomes after LABA therapy is stopped. We used the boundaries for low, medium and high as described in <a href="http://archie.cochrane.org/sections/documents/view?document=z1405201158356969485713945219635%26format=REVMAN#REF-GINA-2014" target="_blank">GINA 2014</a> for ex‐actuator doses. </p> <p>Participants using combination inhalers may be less likely to experience potential adverse effects of LABA treatment, as this removes the risk associated with taking the LABA inhaler without ICS. Combination inhalers may also be associated with generally better compliance with treatment. </p> <p>Differences in stopping different types of LABA may be due to variations in pharmacological properties and duration of action. </p> </section> <section id="CD011306-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses for the primary analyses, excluding the following. </p> <p> <ol id="CD011306-list-0007"> <li> <p>Studies at high risk of bias for blinding.</p> </li> <li> <p>Unpublished data (i.e. no peer‐reviewed full paper available).</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011306-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011306-sec-0054"></div> <section id="CD011306-sec-0055"> <h3 class="title">Description of studies</h3> <p>We included in the <a href="./references#CD011306-sec-0108" title="">Characteristics of included studies</a> section detailed descriptions of studies fulfilling the criteria specified in the protocol. We compiled excluded studies for which full texts were viewed, along with reasons for exclusion, in the <a href="./references#CD011306-sec-0109" title="">Characteristics of excluded studies</a> section. </p> <section id="CD011306-sec-0056"> <h4 class="title">Results of the search</h4> <p>Database searching retrieved 400 references, and our additional searches of industry databases and relevant reference lists yielded 635 records. We removed three duplicates, leaving 1032 unique references. Of these, we excluded 990 after sifting titles and abstracts and assessed full texts of the remaining 42 studies. Twenty‐six of these did not meet the inclusion criteria (<a href="#CD011306-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011306-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011306-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011306-sec-0057"> <h4 class="title">Included studies</h4> <p>Six studies (16 citations) met the inclusion criteria, but one reported no outcomes that could be included in our meta‐analysis (<a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a>). Descriptions from here on will relate to the five studies that contributed data to the meta‐analysis. Those five studies randomly assigned 2781 people with a diagnosis of asthma to the comparisons of interest in this review. <a href="./references#CD011306-bbs2-0003" title="GlaxoSmithKline . Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). OppenheimerJ , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL , et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th international conference; 2004 May 21‐26; Orlando. 2004:J94. ">GSK SAS40037</a> contributed the largest sample size to the analyses, with 824 people randomly assigned across four intervention groups. <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a> included the smallest number of people, with 82 participants randomly assigned to the two arms relevant to this review. </p> <p><b>Design and duration</b> </p> <p>All five studies in the quantitative analysis were multi‐centre, randomised, parallel‐group controlled trials, taking place at between three and 124 centres. One study, <a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a>, was included only in the qualitative analysis and was not a multi‐centre trial. All studies were double‐blind. <a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a> and <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a> had a duration of 12 weeks. The duration of treatment in <a href="./references#CD011306-bbs2-0003" title="GlaxoSmithKline . Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). OppenheimerJ , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL , et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th international conference; 2004 May 21‐26; Orlando. 2004:J94. ">GSK SAS40037</a>, <a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a> and <a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a> was 16 weeks, and <a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a> lasted for 24 weeks but reported its primary outcome at 12 weeks. All studies had a run‐in period, which varied between studies from two weeks to eight weeks, when participants received usual ICS+LABA therapy with rescue SABA. </p> <p><b>Participant inclusion and exclusion criteria</b> </p> <p>We provided detailed explanations of inclusion and exclusion criteria in <a href="./references#CD011306-sec-0108" title="">Characteristics of included studies</a>. All trials included outpatients at least 15 years of age; mean participant age was above 18 years, leading us to treat them as adult studies. All participants had a diagnosis of stable or well‐controlled asthma characterised at study entry, but criteria varied. For inclusion based on stable asthma, <a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a> based definitions of mild to moderate asthma on ICS use, <a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a> assessed whether current asthma therapy controlled asthma, <a href="./references#CD011306-bbs2-0003" title="GlaxoSmithKline . Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). OppenheimerJ , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL , et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th international conference; 2004 May 21‐26; Orlando. 2004:J94. ">GSK SAS40037</a> required a forced expiratory volume of 1 second (FEV<sub>1</sub>) of 40% to 85% of their predicted normal value, <a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a> required an FEV<sub>1</sub> between 40% and 80% of their predicted value and <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a> required that participants had not had an exacerbation in the preceding four weeks. None of the trials used the Global Initiative for Asthma (GINA) definition for mild to moderate asthma or the Asthma Control Questionnaire (ACQ) as part of the inclusion criteria. All trials recruited participants taking regular ICS and LABA therapy with an as‐needed SABA rescue inhaler. Three studies excluded participants with a smoking history ≥ 10 pack‐years (<a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a>; <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>; <a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a>). Four studies excluded people who had recently taken systemic corticosteroids (<a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a>, <a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a> and <a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a> within one month, <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a> within three months). </p> <p><b>Baseline characteristics of participants</b> </p> <p>We extracted baseline characteristics of participants from each trial and presented them in the <a href="./references#CD011306-sec-0108" title="">Characteristics of included studies</a> section, along witha summary in <a href="#CD011306-tbl-0002">Table 1</a>. </p> <div class="table" id="CD011306-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">All included studies — summary characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other ID (s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country (centres)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age, years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LABA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD‐039‐0726</p> <p>D5896C00726</p> <p>NCT00652392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol</p> <p>9 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide</p> <p>320 mcg qd (intervention)</p> <p>160 mcg bd (control)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAM40088</p> <p>SFCF4026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>France (124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone propionate</p> <p>250 mcg bd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0003" title="GlaxoSmithKline . Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). OppenheimerJ , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL , et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th international conference; 2004 May 21‐26; Orlando. 2004:J94. ">GSK SAS40037</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS40037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone propionate</p> <p>100 mcg bd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS40036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone propionate</p> <p>100 mcg bd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAM40031</p> <p>ACTRN12605000465651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone propionate</p> <p>500 mcg bd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Participants were allowed to continue use of their normal rescue inhaler.</p> <p>*Primary outcome peak flow reported at 12 weeks.</p> <p><b>N:</b> number randomly assigned; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonists; <b>ICS:</b> inhaled corticosteroids; R: randomly assigned; <b>DB:</b> double‐blind; <b>PC:</b> placebo‐controlled; qd: once daily; <b>bd:</b> twice daily. </p> </div> </div> <p>Participants' ages across trials had a similar mean value in each trial, ranging from 40 to 49 years. All trials recruited more women than men (between 34.8% male in <a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a> and 49% male in <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>). Trials that provided demographic information described a predominantly Caucasian sample population (ranging from 82.6% to 88% white). Participants' mean percentage predicted FEV<sub>1</sub> was reported in three trials, ranging between 83% and 91% at randomisation (<a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a>; <a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a>; <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>). </p> <p><b>Characteristics of the interventions</b> </p> <p>In all studies, a combination ICS+LABA inhaler was administered before step‐down to LABA, and in four of five studies included in the analysis, the LABA was salmeterol: salmeterol/fluticasone 50/250 mcg twice daily in <a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a> and <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>, and salmeterol/fluticasone 50/100 mcg twice daily in <a href="./references#CD011306-bbs2-0003" title="GlaxoSmithKline . Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). OppenheimerJ , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL , et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th international conference; 2004 May 21‐26; Orlando. 2004:J94. ">GSK SAS40037</a> and <a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a>. In <a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a>, the combination therapy was formoterol/budesonide 9/160 mcg twice daily (<a href="#CD011306-tbl-0002">Table 1</a>). No studies used a different ICS in the comparison group than in the intervention group. All studies used albuterol as the reliever medication in acute exacerbations. </p> <p>The design of <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a> meant that only data reported at week 12 were relevant to this review, as ICS were downtitrated between week 12 and the 52 week endpoint. </p> <p><b>Outcomes and analysis structure</b> </p> <p>Asthma exacerbations were not uniformly defined, but we were able to confirm data for the primary outcome with the author team of another review, who had obtained unpublished information directly from the study sponsors (<a href="./references#CD011306-bbs2-0035" title="BrozekJL , KraftM , KrishnanJA , CloutierMM , LazarusSC , LiJT , et al. Long‐acting β2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine2012;172(18):1365‐75. ">Brozek 2012</a>). We incorporated additional unpublished data from this review for some studies in the ACQ and quality of life analyses with permission from the review authors. We removed these unpublished data in a planned sensitivity analysis. </p> <p>Several measures of asthma control were used in these studies, and not all were validated. We analysed the ACQ and narratively summarised data from other non‐validated measures, including percentage of symptom‐ and rescue‐free days and the number of people meeting GINA definitions for totally controlled and well‐controlled asthma. </p> <p>We subgrouped results according to the ICS+LABA combination used in the comparison group (i.e. fluticasone/salmeterol or budesonide/formoterol), but it was not possible to perform planned subgroup analyses for ICS dose or inhaler type because the studies were similar in these respects. </p> </section> <section id="CD011306-sec-0058"> <h4 class="title">Excluded studies</h4> <p>We excluded 26 records after viewing full texts, in most cases because the study was not designed to test the effects of stopping LABA versus continuing it. We excluded two studies because they used a cross‐over design, which was prespecified as exclusionary in our protocol, and two studies likely to meet the inclusion criteria have not yet been completed (<a href="./references#CD011306-bbs2-0025" title="Long‐acting beta agonist step down study (LASST). http://clinicaltrials.gov/show/NCT01437995 (accessed 10 September 2014). ">NCT01437995</a>; <a href="./references#CD011306-bbs2-0026" title="A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well‐controlled Asthmatic Japanese Subjects. http://clinicaltrials.gov/ct2/show/NCT02094937 (accessed 10 September 2014). ">NCT02094937</a>). We outlined details of reasons for exclusion of studies in the <a href="./references#CD011306-sec-0109" title="">Characteristics of excluded studies</a> section. </p> </section> </section> <section id="CD011306-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>We outlined details of risk of bias for each included study and reasoning behind ratings in <a href="./references#CD011306-sec-0108" title="">Characteristics of included studies</a>, and a summary of risk of bias judgements by study and domain (selection bias, performance bias, detection bias, attrition bias, reporting bias, other bias) can be found in <a href="#CD011306-fig-0002">Figure 2</a>. Most ratings in most domains for included studies were low risk, with the exception of attrition bias and other bias. </p> <div class="figure" id="CD011306-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011306-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011306-sec-0060"> <h4 class="title">Allocation</h4> <p>All of the included studies were described as randomised, but very little published information was available on the methods used in any of the included studies. One study described random sequence generation in sufficient detail to warrant a low risk rating (<a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>), and the other studies were given low risk ratings on the basis of prior contact with study sponsors. <a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a> was published as an abstract and provided inadequate information regarding the randomisation procedure, so bias was rated as unclear. </p> </section> <section id="CD011306-sec-0061"> <h4 class="title">Blinding</h4> <p>Across studies, we found no evidence of risk of bias related to blinding of participants or observers. All studies were described as double‐blind, and study authors described measures such as matched inhalers to hide group allocation from participants and personnel; we therefore assumed that those measuring outcomes were also blinded. </p> </section> <section id="CD011306-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of bias due to high or unbalanced dropout was mixed across studies. We rated one study (<a href="./references#CD011306-bbs2-0003" title="GlaxoSmithKline . Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). OppenheimerJ , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL , et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th international conference; 2004 May 21‐26; Orlando. 2004:J94. ">GSK SAS40037</a>) as high risk because, although all randomly assigned participants were included in the analysis, dropout was high in both groups and was higher in the group for which LABA was stopped, which may have led to underestimation of the effects. We rated two studies as unclear because, although the dropout rate was low overall, it was somewhat unbalanced and was much higher in the ICS group (14%) than in the LABA+ICS group (4%) (<a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>), or the number of withdrawals was not reported (<a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a>); we rated two studies as low risk. </p> </section> <section id="CD011306-sec-0063"> <h4 class="title">Selective reporting</h4> <p>All named outcomes were reported in the published reports or were made available by study authors or sponsors via a previous review team (<a href="./references#CD011306-bbs2-0035" title="BrozekJL , KraftM , KrishnanJA , CloutierMM , LazarusSC , LiJT , et al. Long‐acting β2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine2012;172(18):1365‐75. ">Brozek 2012</a>), and we rated all included studies as low risk. We rated <a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a> as high risk because the data could not be included in the meta‐analysis, and several outcomes were not reported at all. Only a conference abstract was available; therefore this was used for qualitative analysis only. </p> </section> <section id="CD011306-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>During the course of the <a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a> study, recruitment of participants was placed on hold pending analysis of data from the Salmeterol Multicenter Asthma Resarch Trial (SMART) and was subsequently terminated, with approximately 161 participants per treatment group (target was 206 per group). It is unclear whether potential sources of bias threatened the validity of the findings, or the size and direction of the treatment effect. We identified no other sources of bias in the remaining studies. </p> </section> </section> <section id="CD011306-sec-0065"> <h3 class="title" id="CD011306-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD011306-tbl-0001"><b>Summary of findings for the main comparison</b> Stopping LABA compared with continuing use of LABA+ICS for adults with well‐controlled asthma</a> </p> <section id="CD011306-sec-0066"> <h4 class="title">Primary outcomes</h4> <section id="CD011306-sec-0067"> <h5 class="title">Exacerbation requiring systemic corticosteroids</h5> <p>Nineteen people per 1000 who continued their LABA had an exacerbation, compared with 32 per 1000 for whom LABA was stopped (13 more per 1000, 95% CI 3 fewer to 46 more). Confidence intervals did not exclude the possibility that stopping LABA was better (OR 1.74, 95% CI 0.83 to 3.65; participants = 1257; studies = 4; I<sup>2</sup> = 0%; moderate quality; <a href="./references#CD011306-fig-0003" title="">Analysis 1.1</a>), so we downgraded the quality of the evidence for imprecision. A sensitivity analysis using only the published data yielded a slightly larger point estimate with similar imprecision (OR 1.89, 95% CI 0.85 to 4.22). </p> </section> <section id="CD011306-sec-0068"> <h5 class="title">Asthma control</h5> <p>People who stopped their LABA had worse scores on the Asthma Control Questionnaire (ACQ) than those who continued (MD 0.24, 95% CI 0.13 to 0.35; participants = 645; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD011306-fig-0004" title="">Analysis 1.2</a>), but the effect was around half the size of the established minimal clinically important difference (MCID) for this scale, which is 0.5 units (<a href="./references#CD011306-bbs2-0051" title="JuniperEF , O'ByrnePM , GuyattGH , FerriePJ , KingDR . Development and validation of a questionnaire to measure asthma control. European Respiratory Journal1999;14:902‐7. ">Juniper 1999</a>). We rated the evidence as of moderate quality, having downgraded this for possible publication bias because three studies did not report what we considered to be a very important outcome. Data for two of the studies were not available in published reports but were included with permission from <a href="./references#CD011306-bbs2-0035" title="BrozekJL , KraftM , KrishnanJA , CloutierMM , LazarusSC , LiJT , et al. Long‐acting β2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine2012;172(18):1365‐75. ">Brozek 2012</a>, who acquired additional data from the study sponsors for inclusion in their systematic review. Without this unpublished data, the effect favoured continuing LABA to a lesser extent and was very imprecise (MD 0.12, 95% CI ‐0.24 to 0.48). </p> <p>We chose not to meta‐analyse several other measures related to 'control' that were reported in these studies; some were inconsistently reported, and others were not measured on validated scales. Four studies reporting diary card data showed loss of control measured as symptom‐free days, and three saw a reduction in rescue‐free days and night‐time awakenings. These outcomes were considered to provide low‐quality evidence because variation in the magnitude and direction of effects was evident across studies, and because metrics of asthma control were considered indirect or incomplete. </p> <p><a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a> used GINA‐defined criteria for 'well‐controlled' and 'totally controlled' asthma, and found that 47% of those for whom LABA were stopped were considered 'totally controlled' and 77% 'well controlled' after 24 weeks, compared with 73% and 85% of those who continued combination therapy. </p> <p><a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a> measured a 'Total Asthma Score' based on a composite score of asthma symptoms, rescue use and peak flow over the preceding four weeks (<a href="./references#CD011306-bbs2-0057" title="ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Supplementary material for 'Total Asthma Score'. http://bit.ly/1KPUswx (accessed 12 February 2015). ">Reddel 2010 supplement</a>) and found no differences between groups (4.74 (SD 2.21) in those who stopped LABA, 4.54 (SD 2.21) in those who continued LABA). </p> </section> <section id="CD011306-sec-0069"> <h5 class="title">Serious adverse events (all cause)</h5> <p>All studies reported serious adverse events but only 16 events were observed, so it was not clear if stopping LABA was safer than continuing LABA (OR 0.82, 95% CI 0.28 to 2.42; participants = 1342; studies = 5; I<sup>2</sup> = 0%; <a href="./references#CD011306-fig-0005" title="">Analysis 1.3</a>). We downgraded the evidence for imprecision and rated it as moderate quality because confidence intervals included significant benefit and harm for both treatment strategies. None of the data were unpublished, so there was no need to perform a sensitivity analysis. </p> </section> </section> <section id="CD011306-sec-0070"> <h4 class="title">Secondary outcomes</h4> <section id="CD011306-sec-0071"> <h5 class="title">Asthma‐related quality of life</h5> <p>Quality of life declined in those who stopped taking their LABA compared with those who continued, but this was measured on two different scales with different properties, so it is unclear whether the difference was clinically significant (SMD 0.36, 95% CI 0.15 to 0.57; participants = 359; studies = 2; I<sup>2</sup> = 0%). Data for <a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a> were not reported sufficiently in the published reports for inclusion in the meta‐analysis, but complete data were included with permission from <a href="./references#CD011306-bbs2-0035" title="BrozekJL , KraftM , KrishnanJA , CloutierMM , LazarusSC , LiJT , et al. Long‐acting β2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine2012;172(18):1365‐75. ">Brozek 2012</a>, who acquired additional data from the study sponsors. <a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a> also reported a responder analysis for the Asthma Quality of Life Questionnaire (AQLQ) (6.6% vs 14%) that was not statistically significant but supported the findings of the main AQLQ analysis. Evidence was rated of moderate quality because the outcome was available in only two of the included studies, so we deemed that publication bias was possible. </p> </section> <section id="CD011306-sec-0072"> <h5 class="title">Exacerbations requiring hospitalisation or emergency department visit</h5> <p>None of the included studies reported this outcome separately, so no data were available for analysis. We downgraded the evidence twice for imprecision and rated the quality as low, but the lack of events might have reflected the length of studies conducted or the severity of participants recruited. </p> </section> <section id="CD011306-sec-0073"> <h5 class="title">Adverse events (all cause)</h5> <p>Fewer people who stopped their LABA had adverse events, although the upper confidence interval did not exclude the possibility that stopping LABA was harmful (OR 0.83, 95% CI 0.66 to 1.05; participants = 1339; studies = 5; I<sup>2</sup> = 4%; <a href="./references#CD011306-fig-0008" title="">Analysis 1.6</a>). We downgraded the evidence for this imprecision and rated the quality as moderate. </p> </section> <section id="CD011306-sec-0074"> <h5 class="title">Withdrawals</h5> <p>More people who stopped taking their LABA dropped out before completion of the studies (OR 1.95, 95% CI 1.47 to 2.58; participants = 1352; studies = 5; I<sup>2</sup> = 6%; <a href="./references#CD011306-fig-0009" title="">Analysis 1.7</a>). We planned to look at total withdrawals, as they are not affected by the possible bias of assigning reasons for dropouts, but for this reason, we were unable to make assumptions about why participants were more likely to withdraw from the trial if they stopped their LABA than if they continued LABA. We downgraded the evidence for indirectness for this reason and rated the quality as moderate. </p> </section> </section> <section id="CD011306-sec-0075"> <h4 class="title">Subgroup analyses</h4> <section id="CD011306-sec-0076"> <h5 class="title">Mean ICS dose</h5> <p>All studies reporting exacerbations requiring systemic steroids used ICS doses classified as low in <a href="./references#CD011306-bbs2-0045" title="Global Initiative for Asthma(GINA) . Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014). ">GINA 2014</a>, so it was not possible to perform the subgroup analysis. </p> </section> <section id="CD011306-sec-0077"> <h5 class="title">Inhaler type</h5> <p>All studies reporting exacerbations requiring oral steroids used combination inhalers, so it was not possible to perform the subgroup analysis. </p> </section> <section id="CD011306-sec-0078"> <h5 class="title">Type of LABA</h5> <p>We subgrouped included studies by the LABA that was delivered in the comparison group. Three studies reporting exacerbations requiring systemic steroids used salmeterol and one used formoterol, and the test for subgroup differences was not significant (I<sup>2</sup> = 0%; <a href="./references#CD011306-fig-0010" title="">Analysis 2.1</a>). Confidence intervals for each subgroup effect were very wide because of the small quantity of available data, so it is difficult to know whether a difference was present that was not detected. For asthma control measured on the ACQ, the effect favouring continuing LABA was larger in the study using formoterol than in the two using salmeterol, but the test for subgroup differences was not significant (I<sup>2</sup> = 28%, P = 0.24; <a href="./references#CD011306-fig-0011" title="">Analysis 2.2</a>), and this determination was based on a very small number of studies. For serious adverse events, the effect was more in favour of stopping LABA in the formoterol study than in the four that used salmeterol, but confidence intervals were very wide and overlapping; the test for subgroup differences was not significant (I<sup>2</sup> = 0%; <a href="./references#CD011306-fig-0012" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD011306-sec-0079"> <h4 class="title">Sensitivity analysis</h4> <section id="CD011306-sec-0080"> <h5 class="title">Studies at high risk of bias for blinding</h5> <p>We rated no studies as having high risk of bias for either of the blinding domains, so a sensitivity analysis on this basis was not necessary. </p> </section> <section id="CD011306-sec-0081"> <h5 class="title">Unpublished data</h5> <p>We removed from the primary outcomes in sensitivity analyses additional unpublished data included with permission from the authors of <a href="./references#CD011306-bbs2-0035" title="BrozekJL , KraftM , KrishnanJA , CloutierMM , LazarusSC , LiJT , et al. Long‐acting β2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine2012;172(18):1365‐75. ">Brozek 2012</a>. . We reported these results under each of the primary outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011306-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011306-sec-0082"></div> <section id="CD011306-sec-0083"> <h3 class="title" id="CD011306-sec-0083">Summary of main results</h3> <p>Six randomised, double‐blind studies between 12 and 24 weeks long met the inclusion criteria. The five studies contributing data assigned 2781 people with stable asthma to the comparison of interest (stepping down from LABA+ICS to ICS alone) or to the control group (continuation of LABA+ICS), although the definition of stable asthma and the inclusion criteria varied across studies. </p> <p>In the primary analysis, evidence from four studies indicated that stopping LABA might increase the number of people having exacerbations requiring systemic corticosteroids, but the effect was not statistically significant, as the confidence intervals did not exclude the possibility that stopping LABA was beneficial; over 17 weeks, 19 people per 1000 who continued their LABA had an exacerbation, compared with 32 per 1000 for whom LABA was stopped (13 more per 1000, 95% CI 3 fewer to 46 more). </p> <p>Moderate‐quality evidence suggests that stopping LABA was associated with loss of asthma control as measured by the ACQ and with worse asthma‐related quality of life than for those who continued LABA, but the effects were not clinically significant. Other unvalidated measures of control, such as symptom‐free days and use of reliever medication, were presented in a narrative synthesis and showed variable results. No included study reported exacerbations requiring an emergency department visit or hospitalisation as a separate outcome. </p> <p>Serious adverse events were too rare in these studies to show whether stopping LABA was better or worse than continuing LABA; this may be a reflection of the severity of illness among participants and of study duration. Stopping LABA may result in fewer adverse events of any kind compared with continuing LABA, but this effect was not statistically significant, and stopping LABA made people more likely to withdraw from research studies. </p> </section> <section id="CD011306-sec-0084"> <h3 class="title" id="CD011306-sec-0084">Overall completeness and applicability of evidence</h3> <p>We were unable to perform the subgroup analyses that we had set out in the protocol. As all of the studies reporting exacerbations requiring systemic steroids used ICS doses classified as low in <a href="./references#CD011306-bbs2-0045" title="Global Initiative for Asthma(GINA) . Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014). ">GINA 2014</a>, and as all used combination inhalers, it was not possible to perform subgroup analyses for mean ICS dose or for inhaler type. </p> <p>Although all included studies had stable asthma as part of their inclusion criteria, no standardised internationally recognised severity parameter grading system such as <a href="./references#CD011306-bbs2-0045" title="Global Initiative for Asthma(GINA) . Global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf (accessed 19 June 2014). ">GINA 2014</a> (or other severity scoring systems) was used. This would have reduced potential clinical heterogeneity between studies and would have increased applicability for a clinical audience. Treatment protocols for the intervention varied between studies in terms of medication, dosage and frequency, and inconsistencies in how LABA was stepped down were observed. </p> <p>Some outcomes with great clinical importance, such as quality of life, were sparsely reported, with only two studies providing data on these. In addition, we could not comment on long‐term effects of stopping LABA, as all included studies were of relatively short duration — between 12 and 24 weeks — possibly not sufficient for long‐term effects to become apparent. Serious adverse events were reported at the end of each study period, and if further events occurred beyond this time, they could not be recorded, which may impact the completeness of evidence. A recent overview of LABA safety in asthma highlighted three ongoing long‐term trials that will be best placed to assess the safety implications of prolonged combination therapy (<a href="./references#CD011306-bbs2-0039" title="CatesCJ , WielandLS , OleszczukM , KewKM . Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD010314.pub2] ">Cates 2014</a>). </p> <p>Baseline demographics indicated a Caucasian bias among participants. A more diverse study population would increase generalisability of the results. </p> </section> <section id="CD011306-sec-0085"> <h3 class="title" id="CD011306-sec-0085">Quality of the evidence</h3> <p>Review authors assessed the quality of the outcome data by using GRADEpro software and recommendations provided by The Cochrane Collaboration; we summarised results of this analysis in <a href="./full#CD011306-tbl-0001">summary of findings Table for the main comparison</a>. We assessed all outcomes except exacerbations requiring hospital admission or an emergency department visit as of moderate quality, but we downgraded evidence quality for a variety of reasons. Heterogeneity across individual outcomes was not statistically significant, as reflected by low I<sup>2</sup> values. </p> <p>We downgraded both asthma control and asthma‐related quality of life on the basis that although they are important patient‐centred outcomes, they were not reported by investigators in at least three of the studies. </p> <p>We downgraded the evidence for exacerbations requiring systemic corticosteroids and for exacerbations requiring hospital or emergency department treatment because of imprecision. In the case of exacerbations requiring systemic corticosteroids, confidence intervals show both significant harm and possible benefit of stopping LABA. For exacerbations requiring hospital or emergency department treatment, no events were observed. This may reflect both duration of the trials and asthma severity in the studied populations. Similarly, evidence for both serious adverse events and all adverse events was downgraded because of imprecision. </p> <p>Indirectness is more challenging to assess. The recruited population of participants with stable asthma may not have been the most appropriate group on whom to assess outcomes such as exacerbations requiring systemic corticosteroids and hospital admission, given the short duration of the studies, leading to few events and imprecision. However, all outcomes are directly clinically relevant and are not surrogate markers. </p> <p>To resolve uncertainties related to risk of bias and missing data, we made an effort to contact all study authors. We received an acknowledgement of contact from <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>, <a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a> and <a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a>. <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a> provided additional data, and we received no response from <a href="./references#CD011306-bbs2-0003" title="GlaxoSmithKline . Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). OppenheimerJ , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL , et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th international conference; 2004 May 21‐26; Orlando. 2004:J94. ">GSK SAS40037</a>. </p> </section> <section id="CD011306-sec-0086"> <h3 class="title" id="CD011306-sec-0086">Potential biases in the review process</h3> <p>Standard Cochrane methods were used to create this review process. Two independent review authors extracted study characteristics and numerical data and resolved discrepancies through discussion and, if necessary, consultation with a third independent review author. Two independent review authors also made risk of bias decisions. Review authors reported no conflicts of interest. Two independent review authors performed extensive literature searches and subsequent screening of published data and conference abstracts. Studies were not limited by language of publication. Given that a thorough search strategy was used, it is unlikely that any available published studies were missed by the study selection process. Review authors also attempted to contact all study authors to obtain additional information about outcomes and to clarify study methods to ensure accurate risk of bias decisions. We received detailed replies and additional data from one study author; others did not receive the request or were unable to provide the information requested. </p> </section> <section id="CD011306-sec-0087"> <h3 class="title" id="CD011306-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>We identified an existing systematic review conducted by <a href="./references#CD011306-bbs2-0035" title="BrozekJL , KraftM , KrishnanJA , CloutierMM , LazarusSC , LiJT , et al. Long‐acting β2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine2012;172(18):1365‐75. ">Brozek 2012</a> to assess evidence supporting discontinuation of LABA therapy in adults and older children with stable asthma controlled by a combination of ICS and LABA. We included supplemental data from this review in this Cochrane review with their permission. Their inclusion criteria differed from ours, as they included children (lower limit age cutoff was four years) and restricted LABA type to salmeterol or formoterol. Their search strategy yielded the same five studies identified by our independent search strategy (<a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a>; <a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a>; <a href="./references#CD011306-bbs2-0003" title="GlaxoSmithKline . Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). OppenheimerJ , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL , et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th international conference; 2004 May 21‐26; Orlando. 2004:J94. ">GSK SAS40037</a>; <a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a>; <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>). We identified these and an additional study (<a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a>), although this latter study could not be included in our quantitative analysis, as we had insufficient information beyond the abstract. The conclusion from <a href="./references#CD011306-bbs2-0035" title="BrozekJL , KraftM , KrishnanJA , CloutierMM , LazarusSC , LiJT , et al. Long‐acting β2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine2012;172(18):1365‐75. ">Brozek 2012</a> was that no statistically significant results were reported for any outcomes that would demonstrate benefit derived from LABA step‐down compared with continued use of LABA and ICS. </p> <p><a href="./references#CD011306-bbs2-0035" title="BrozekJL , KraftM , KrishnanJA , CloutierMM , LazarusSC , LiJT , et al. Long‐acting β2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine2012;172(18):1365‐75. ">Brozek 2012</a> assessed additional outcomes, such as morning peak flow and prebronchodilator peak flow rates, and included unpublished quality of life data. Disagreements regarding evidence quality ratings were noted between this review and <a href="./references#CD011306-bbs2-0035" title="BrozekJL , KraftM , KrishnanJA , CloutierMM , LazarusSC , LiJT , et al. Long‐acting β2‐agonist step‐off in patients with controlled asthma. Archives of Internal Medicine2012;172(18):1365‐75. ">Brozek 2012,</a> with the latter downgrading most outcomes for indirectness because review authors noted that studies did not always make clear whether participants were well controlled on long‐term combination therapy, or whether they had been given combination therapy during a run‐in as part of the study. They also noted the issue regarding the short duration of studies with particular relevance to the outcomes for which events were rare (e.g. hospital admissions, serious adverse events). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011306-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011306-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011306-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 1 Exacerbation: systemic corticosteroids." data-id="CD011306-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 1 Exacerbation: systemic corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 2 Asthma control: ACQ." data-id="CD011306-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 2 Asthma control: ACQ.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 3 Serious adverse events." data-id="CD011306-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 4 Asthma‐related quality of life." data-id="CD011306-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 4 Asthma‐related quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 5 Exacerbation: hospital admission or emergency department visit." data-id="CD011306-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 5 Exacerbation: hospital admission or emergency department visit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 6 Adverse events (all cause)." data-id="CD011306-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 6 Adverse events (all cause).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 7 Withdrawals (all)." data-id="CD011306-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 7 Withdrawals (all).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis: type of LABA, Outcome 1 Exacerbation: requiring systemic corticosteroids." data-id="CD011306-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis: type of LABA, Outcome 1 Exacerbation: requiring systemic corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis: type of LABA, Outcome 2 Asthma control: ACQ." data-id="CD011306-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis: type of LABA, Outcome 2 Asthma control: ACQ.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011306-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/urn:x-wiley:14651858:media:CD011306:CD011306-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_t/tCD011306-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis: type of LABA, Outcome 3 Serious adverse events." data-id="CD011306-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis: type of LABA, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/media/CDSR/CD011306/image_n/nCD011306-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011306-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Stopping LABA compared with continuing use of LABA+ICS for adults with well‐controlled asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Stopp ing LABA compared with continuing use of LABA+ICS for adults with well‐controlled asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with asthma well controlled on LABA and ICS<br/> <b>Settings</b> : outpatient<br/> <b>Intervention</b> : LABA stopped<br/> <b>Comparison</b>: LABA continued </p> <p>Both groups were taking the same dose of ICS</p> <p><b>Time point</b>: calculated as the weighted mean duration of studies contributing to each analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>LABA continued</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> LABA stopped</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation: systemic corticosteroids</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (16 to 65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.74</b> <br/> (0.83 to 3.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1257<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma control: ACQ</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ACQ score in the control group was 0.68<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean score of people who stopped LABA was <b>0.24 points worse</b> (0.13 higher to 0.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>645<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID = 0.5, so difference is not clinically significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (4 to 31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.82</b> <br/> (0.28 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1342<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma‐related quality of life</b> </p> <p>12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean asthma‐related quality of life in the control group was 1.18</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean score of people who stopped LABA was <b>0.36 standard deviations worse</b> (0.15 worse to 0.57 worse) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>359<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c,</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation: hospital</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1342<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No one in either group was hospitalised for an asthma exacerbation</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (all)</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>521 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000<br/> (417 to 533) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b> <br/> (0.66 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1339<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal (all)</b> </p> <p>17 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>269 per 1000<br/> (217 to 327) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.95</b> <br/> (1.47 to 2.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1352<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g.median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : Confidence interval; <b>OR</b> : Odds ratio; <b>LABA</b>: Long‐acting beta<sub>2</sub>‐agonists; <b>ICS</b> : Inhaled corticosteroids; <b>ACQ</b> : Asthma Control Questionnaire; <b>AQLQ</b>: Asthma Quality of Life Questionnaire. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality</b> : Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Confidence intervals include both significant harm and possible benefit of stopping LABA. </p> <p><sup>b</sup>Confidence intervals include significant benefit and harm of either treatment strategy, and 16 events were reported across all studies. </p> <p><sup>c</sup>Quality of life and asthma control are important patient‐centred outcomes and were not reported by at least 3 studies (‐1 publication bias). </p> <p><sup>d</sup>Difficult to judge imprecision because the data were analysed with SMD (Reddel used the Marks AQLQ, and Berger used the Juniper, which are coded in opposite directions on different scales). The Juniper has an MCID of 0.5, and the MD between groups in this study was 0.37 (no downgrade). </p> <p><sup>e</sup>No events were observed, so it was impossible to discern a difference between groups. This may be due to the length of the trials and the severity of illness of the population (‐2 imprecision). </p> <p><sup>f</sup>Confidence intervals include significant benefit of stopping LABA and do not exclude benefit of continuing LABA. </p> <p><sup>g</sup>We planned to look at total withdrawal as it is not affected by the possible bias of assigning reasons for dropouts, but for this reason we were unable to make assumptions about why participants were more likely to withdraw from the trial if they stopped their LABA. </p> <p><sup>h</sup>Weighted mean of control group scores in <a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a> and <a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a> (<a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a> not included in calculation, as researchers reported data as change from baseline). </p> <p><sup>i</sup>Control group endpoint score on the Marks AQLQ in <a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a>. <a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a>, the only other study in the analysis, reported change from baseline on the Juniper scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Stopping LABA compared with continuing use of LABA+ICS for adults with well‐controlled asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011306-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">All included studies — summary characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Other ID (s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country (centres)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age, years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LABA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0001" title="AstraZeneca . A 12‐week randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma. http://www.astrazenecaclinicaltrials. com/ (accessed 10 September 2014). [AstraZeneca: SD‐039‐0726] BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. ">Berger 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD‐039‐0726</p> <p>D5896C00726</p> <p>NCT00652392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formoterol</p> <p>9 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Budesonide</p> <p>320 mcg qd (intervention)</p> <p>160 mcg bd (control)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0002" title="GlaxoSmithKline . Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long‐acting inhaled 2‐agonist. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). GodardP , AttaliV . Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]. American Thoracic Society International Conference; 2006 May 19‐24; San Diego. 2006:A213. GodardP , GreillierP , PigeariasB , NachbaurG , DesfougeresJ‐L , AttaliV . Maintaining asthma control in persistent asthma: comparison of three strategies in a 6‐month double‐blind randomised study. Respiratory Medicine2008;102(8):1124‐31. ">Godard 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAM40088</p> <p>SFCF4026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>France (124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone propionate</p> <p>250 mcg bd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0003" title="GlaxoSmithKline . Randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). OppenheimerJ , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL , et al. “Stepping down” from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control. American Thoracic Society 100th international conference; 2004 May 21‐26; Orlando. 2004:J94. ">GSK SAS40037</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS40037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone propionate</p> <p>100 mcg bd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0004" title="DorinskyP , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanB , SuttonL . Stepping down from fluticasone propionate/salmeterol 100/50mcg Diskus results in loss of asthma control [abstract]. European Respiratory Journal2004;(suppl 48):309s. DorinskyPM , StaufferJ , Waitkus‐EdwardsK , YanceyS , PrillamanBA , SuttonL . &quot;Stepping down&quot; from fluticasone propionate/salmeterol 100/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]. Chest2004;126:758S‐a. GlaxoSmithKline . A multicenter, randomized, double‐blind, double‐dummy, parallel group, 16‐week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol Diskus combination product 100/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). KoenigS , Waitkus‐EdwardsK , YanceyS , PrillamanB , DorinskyP . Loss of asthma control when patients receiving fluticasone propionate/salmeterol 100/50μg Diskus are “stepped down” to fluticasone propionate, salmeterol or montelukast alone. Journal of Allergy &amp; Clinical Immunology2004;113:S94. KoenigSM , OstromN , PearlmanD , Waitkus‐EdwardsK , YanceyS , PrillamanBA , et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are 'stepped‐down'. Journal of Asthma2008;45:681‐7. ">Koenig 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS40036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA (85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone propionate</p> <p>100 mcg bd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0005" title="GlaxoSmithKline . A 13month, randomised, double‐blind, parallel‐group comparison of the efficacy of Seretide (fluticasone propionate/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down‐titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500/50 mcg twice daily for at least 4wk. http://www.gsk‐clinicalstudyregister.com/ (accessed 10 September 2014). ReddelHK , GibsonPG , PetersMJ , WarkPAB , SandIB , HoyosCM , et al. Down‐titration from high‐dose combination therapy in asthma: removal of long‐acting beta(2)‐agonist. Respiratory Medicine2010;104:1110‐20. ReddelHK , PeytersMJ , WarkPA , SandIB , JenkinsCR . Comparison of the efficacy of Seretide and Flixotide when down‐titrating the inhaled corticosteroid dose. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25‐28; Auckland. 2007:TP041. ">Reddel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAM40031</p> <p>ACTRN12605000465651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluticasone propionate</p> <p>500 mcg bd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011306-bbs2-0006" title="SlankardML , CanfieldS , MichelisM , MansukhaniM , McGoeyB , PaigeA , et al. ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]. Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)2011;127(2):AB67. ">Slankard 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>R, DB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salmeterol</p> <p>50 mcg bd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Participants were allowed to continue use of their normal rescue inhaler.</p> <p>*Primary outcome peak flow reported at 12 weeks.</p> <p><b>N:</b> number randomly assigned; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonists; <b>ICS:</b> inhaled corticosteroids; R: randomly assigned; <b>DB:</b> double‐blind; <b>PC:</b> placebo‐controlled; qd: once daily; <b>bd:</b> twice daily. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">All included studies — summary characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/full#CD011306-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011306-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Stopped LABA vs continued LABA+ICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbation: systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.83, 3.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asthma control: ACQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.13, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.28, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Asthma‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.15, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Exacerbation: hospital admission or emergency department visit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events (all cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.66, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.47, 2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Stopped LABA vs continued LABA+ICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011306-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: type of LABA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbation: requiring systemic corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.83, 3.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [0.19, 23.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.78, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asthma control: ACQ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.13, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.15, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.05, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.28, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.04, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.31, 3.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: type of LABA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011306.pub2/references#CD011306-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011306.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011306-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011306-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011306-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011306-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011306-note-0002">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011306\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011306\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011306\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011306\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011306\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011306.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011306.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011306.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011306.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011306.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716287426"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011306.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716287430"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011306.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9bd62c971bf6',t:'MTc0MDcxNjI4Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 